Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo GOLD™ Functional Grade
Product No.: C793
Clone MIG-2F5-5 Target CXCL9 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names MIG-1, MIG Isotype IgG Applications FC , IF , in vivo , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Recommended Dilution Buffer Immunogen Mouse plasmacytoid dendritic cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco FC Additional Applications Reported In Literature ? N
IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity MIG-2F5-5 activity is directed against murine CXCL9 (monokine induced by gamma interferon, MIG). Background CXCL9 is a chemokine, which are small 8-15 kDa proteins that function in immune responses1. CXCL9, -10, -11 and their receptor CXCR3 regulate immune cell migration, differentiation, and activation, leading to tumor suppression in the paracrine axis. However, in the autocrine axis, they may be involved in tumor growth and metastasis. The CXCL9, -10, -11/CXCR3 axis also regulates differentiation of naïve T cells to T helper 1 (Th1) cells. CXCL9, -10, and -11 are usually expressed at low levels but are upregulated by cytokine stimulation. CXCL9 is dependent on IFNγ for expression2. CXCL9 is also capable of direct antimicrobial activity against pathogen infection3.
CXCL9 is secreted by macrophages4, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ1 and is also expressed in intratumoral dendritic cells5. CXCL9 is also detectable in CD103+ conventional dendritic cells (cDCs) isolated from transgenic murine MMTV-PyMT tumors following in vivo administration of brefeldin A5. Additionally, CXCL9 is detectable in myeloid cells following ex vivo stimulation with IFN-γ. Furthermore, CXCL9 expression is enhanced in CD8α+ cDC1s when anti-TIM-3 is added. Neutralizing antibodies against Galectin-9 lead to an increase in CXCL9 expression comparable to that induced by anti-TIM-3 antibody. Additionally, endothelial cell expression of CXCL9 is strongly increased in liver sinusoidal endothelial cells isolated from nonalcoholic steatohepatitis mouse livers6.
MIG-2F5-5 was generated by immunizing male Armenian hamsters with recombinant murine CXCL9, and specificity was confirmed by ELISA7.
Antigen Distribution CXCL9 is mainly secreted by macrophages, monocytes, endothelial cells, fibroblasts, and cancer cells in response to IFN-γ and is also expressed in intratumoral dendritic cells. NCBI Gene Bank ID UniProt.org Research Area Immunology . Chemokine Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone MIG-2F5-5 is a monoclonal antibody widely used in in vivo mouse studies to neutralize mouse CXCL9 (also known as MIG, Monokine Induced by Gamma interferon), a chemokine crucial for immune cell recruitment during inflammation and immune responses. In vivo, MIG-2F5-5 is administered to mice to block or neutralize endogenous CXCL9 activity, thereby allowing researchers to study the physiological and pathological roles of CXCL9. Here are key points about its usage:
Research involving this antibody has clarified CXCL9's contribution to T cell recruitment, tumor immune infiltration, and inflammatory responses. The antibody's specificity for mouse CXCL9 is validated by ELISA and other methods. When planning in vivo experiments, typical protocols involve antibody injection (intraperitoneal or intravenous) at doses and schedules optimized for the specific study objective and disease model. In summary, clone MIG-2F5-5 is a validated reagent for functional inhibition of mouse CXCL9 in live animal studies, primarily to dissect the chemokine's role in immune cell trafficking and its broader immunological effects. The correct storage temperature for the sterile packaged clone MIG-2F5-5 (anti-Mouse CXCL9) is 2–8°C (refrigerator temperature) for up to one month. For longer-term storage, it is recommended to aseptically aliquot the antibody in working volumes (without diluting) and store at -70°C (ultra-low freezer). Avoid repeated freeze-thaw cycles to maintain antibody integrity. Based on the available information, there are limited specific details about commonly co-used antibodies or proteins with MIG-2F5-5 in the literature. However, the search results do provide some insights into related molecules and experimental contexts. Related Antibodies and ProteinsThe search results mention a few specific antibodies that have been used in research contexts involving CXCL9 and the MIG-2F5-5 antibody: Anti-TIM-3 antibodies are mentioned as being used in conjunction with CXCL9 research, where anti-TIM-3 treatment enhances CXCL9 expression in CD8?+ cDC1 dendritic cells. Anti-Galectin-9 neutralizing antibodies have been used in studies examining CXCL9 expression, with these antibodies leading to increased CXCL9 expression comparable to anti-TIM-3 antibody effects. CXCL9 Pathway ComponentsSince MIG-2F5-5 targets CXCL9, research involving this antibody likely intersects with other components of the CXCL9 signaling pathway: CXCR3 receptor is the primary receptor for CXCL9, and antibodies or reagents targeting CXCR3 would be relevant in functional studies. Related chemokines including CXCL10 and CXCL11 are frequently studied alongside CXCL9, as they share the CXCR3 receptor and have overlapping functions in immune cell migration and activation. Cellular Context MarkersGiven that CXCL9 is expressed by various cell types, researchers using MIG-2F5-5 likely employ cell-type-specific markers:
The search results indicate that MIG-2F5-5 has applications in flow cytometry, immunofluorescence, and neutralization studies, suggesting it's commonly used alongside fluorescent markers and other detection antibodies in these experimental contexts. Clone MIG-2F5-5 (also referenced as MIG-2F5.5) is a monoclonal antibody that specifically targets mouse CXCL9 (also known as MIG, Monokine Induced by Gamma Interferon), and is widely cited in studies investigating immune cell dynamics, T cell recruitment, and tumor immune microenvironments. Key findings from scientific literature citing clone MIG-2F5-5:
Summary table:
Additional context:
If you require specific publication summaries or direct study outcomes, please clarify the context or desired research focus. References & Citations1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
2. Cole KE, Strick CA, Paradis TJ, et al. J Exp Med. 187: 2009–2021. 1998. 3. Reid-Yu SA, Tuinema BR, Small CN, et al. PLoS Pathog. 11(2):e1004648. 2015. 4. Marcovecchio PM, Thomas G, Salek-Ardakani S. J Immunother Cancer. 9(2):e002045. 2021. 5. de Mingo Pulido Á, Gardner A, Hiebler S, et al. Cancer Cell. 33(1):60-74.e6. 2018. 6. Xiong X, Kuang H, Ansari S, et al. Mol Cell. 75(3):644-660.e5. 2019. 7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002. 8. Asai A, Tsuda Y, Kobayashi M, et al. Infect Immun. 78(10):4311-4319. 2010. Technical ProtocolsCertificate of Analysis |
Formats Available
